Arcturus Therapeutics Holdings Inc. Reports Results of 2026 Annual Stockholders Meeting
San Diego, CA – June 5, 2026 – Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company, announced the results of its 2026 Annual Meeting of Stockholders, held on June 5, 2026. The meeting addressed several key proposals, all of which were approved by shareholders, with the potential to shape the company’s strategic direction in the upcoming year.
Key Highlights from the Meeting
- Quorum Achieved: Out of 28,423,069 shares of common stock entitled to vote, holders of 21,435,189 shares were present in person or by proxy, establishing a quorum for the meeting.
- Election of Directors: Shareholders elected the following individuals to the Board of Directors, each to serve until the next annual meeting:
- Dr. Peter Farrell
- Joseph E. Payne
- James Barlow
- Dr. Edward W. Holmes
- Dr. Magda Marquet
- Dr. Jing L. Marantz
- Dr. John Kels
- Dr. Moncef Slaoui
This broad re-election signals ongoing leadership stability and continued execution of Arcturus’ strategic vision in the competitive RNA therapeutics sector.
- Executive Compensation (“Say-on-Pay”): The company’s executive compensation plan was approved on a non-binding advisory basis, with a strong “For” vote (15,254,240 in favor, 327,647 against, 176,375 abstain, and 5,676,927 broker non-votes). This demonstrates shareholder support for current executive pay practices and could bolster management morale and retention.
- Ratification of Deloitte & Touche LLP: Shareholders decisively ratified the appointment of Deloitte & Touche LLP as Arcturus’ independent registered public accounting firm for the fiscal year ending December 31, 2026. This decision ensures the continuity of financial oversight and audit quality, which is critical for investor confidence.
Potential Price-Sensitive Information
- Corporate Governance Stability: The re-election of the entire slate of directors, including key scientific and industry leaders, signals strategic continuity and could be viewed positively by the market.
- Strong Shareholder Support for Executive Compensation: The “say-on-pay” vote outcome reflects robust investor confidence in the company’s leadership and compensation structure, suggesting alignment between management and shareholder interests.
- Assurance of Financial Controls: The ratification of a top-tier audit firm (Deloitte & Touche LLP) supports the company’s commitment to transparency and compliance, potentially reducing perceived risk for investors.
Other Noteworthy Details
- Company and Security Information:
- Business Address: 10285 Science Center Drive, San Diego, CA 92121
- Trading Symbol: ARCT
- Exchange: NASDAQ
- Common Stock Outstanding as of Meeting Date: 28,423,069 shares
- Emerging Growth Company Status: Arcturus is no longer considered an emerging growth company, which may attract increased attention from institutional investors and analysts.
Conclusion
The 2026 Annual Meeting of Arcturus Therapeutics Holdings Inc. delivered solid signals of stability and continued shareholder support. No surprises or contentious issues arose, and all proposals were passed with clear majorities, including the endorsement of the company’s leadership team, executive compensation, and auditor. Investors may view these outcomes as positive, reinforcing confidence in the company’s governance and ongoing strategic plan in the RNA medicines space.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence or consult their financial advisor before making any investment decisions. The information provided is based on the company’s SEC filings as of June 5, 2026, and may be subject to change.
